Insider Selling Continues at Plexus Corp. The recent Form 4 filed by director Karen M. Rapp shows a sale of 1,000 shares of Plexus Corp. common stock on June 1, 2026, executed at a price of $270 per share under a Rule 10b5‑1 plan adopted earlier that month. The transaction reduces Rapp’s holdings to 8,035 shares—roughly 0.11 % of outstanding equity—after a series of buy‑sell swings that have characterized her trading pattern over the past year.
What This Means for Investors Rapp’s activity is consistent with a disciplined plan rather than opportunistic trading; her last sale in late February also used a 10b5‑1 plan, and the timing aligns with the company’s strong earnings momentum. Plexus has posted a 9.56 % month‑over‑month gain and a 118.76 % YTD rally, buoyed by expanding EMS contracts across defense and aerospace. While the sale may signal a portfolio rebalancing, it does not appear to undermine confidence in the firm’s long‑term prospects, especially given the limited percentage of her stake and the absence of any material insider concern flagged by the SEC.
Rapp Karen Marie: A Brief Profile Since early 2025, Rapp has executed a series of 500‑share sales interspersed with 1,008‑share purchases of restricted‑stock‑units, often alternating between buying and selling within weeks. Her most recent sale on February 27 fetched $195.59 per share, and the June transaction at $270 reflects a modest 0.03 % price change from the prevailing $287.65 market price. The pattern suggests a preference for structured, plan‑based exits rather than market‑timed trades. For investors, this signals a measured approach to liquidity needs without overtly signaling a loss of faith in Plexus’s trajectory.
Company‑Wide Insider Trends The broader insider landscape remains active: CEO Kelsey Todd has sold multiple blocks of shares since May, and other executives such as Ninivaggi, Jermain, and Mihm have also trimmed positions. These moves are largely consistent with vesting schedules and regulatory compliance rather than bearish sentiment. The combined insider activity has not eroded market confidence; the stock’s 52‑week high remains near $283, and the price‑earnings ratio of 39.43 positions Plexus within the premium range for EMS players, reflecting investors’ expectations of continued growth.
Bottom Line for Stakeholders Karen Rapp’s June sale is a routine 10b5‑1 execution that does not signal distress. For shareholders, the move underscores the importance of monitoring insider plans but also highlights the resilience of Plexus’s business model amid a sector poised for sustained demand. As the company continues to secure high‑profile EMS contracts, the short‑term insider liquidity will likely have minimal impact on long‑term valuation trends.
| Date | Owner | Transaction Type | Shares | Price per Share | Security |
|---|---|---|---|---|---|
| 2026-06-01 | Rapp Karen Marie () | Sell | 500.00 | 270.00 | Common Stock, $.01 par value |
